Literature DB >> 6187722

Enhancement of antitumor activity of bleomycin by benzamide in vitro and in vivo.

H Sakamoto, H Kawamitsu, M Miwa, M Terada, T Sugimura.   

Abstract

The cytotoxic effects of bleomycin on HeLa cells in culture were enhanced by incubation of the cells with benzamide, a potent inhibitor of poly(ADP-ribose) polymerase, at concentrations at which benzamide alone did not show any cytotoxicity. Benzamide plus bleomycin display enhanced therapeutic effects against Ehrlich ascites tumor cells in vivo. On daily treatment with various doses of bleomycin plus benzamide for 10 days, mice with Ehrlich ascites tumors survived longer than mice on treatment with bleomycin alone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187722     DOI: 10.7164/antibiotics.36.296

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines.

Authors:  S Kubo; M Matsutani; K Nakagawa; T Ogura; H Esumi; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy.

Authors:  N A Berger; S J Berger; D M Catino; S J Petzold; R K Robins
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.

Authors:  M R Horsman; D M Brown; D G Hirst; J M Brown
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

4.  High induction of poly(ADP-ribose) polymerase activity in bleomycin-resistant HeLa cells.

Authors:  M Urade; M Sugi; T Mima; T Ogura; T Matsuya
Journal:  Jpn J Cancer Res       Date:  1989-05

5.  Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.

Authors:  M R Horsman; D J Chaplin
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.